Filing Flows › Bioventus (BVS) › R&D spending
Bioventus (BVS) R&D spending by quarter
Bioventus' R&D spending was $3.4M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $2.5M (Q1 2026) to $3.4M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.4M | +8% | +18% |
| Q2 2026 | $3.2M | +29% | 0% |
| Q1 2026 | $2.5M | -18% | -18% |
| Q4 2025 | $3.0M | +3% | — |
| Q3 2025 | $2.9M | -8% | — |
| Q2 2025 | $3.2M | +5% | — |
| Q1 2025 | $3.0M | — | — |
Q3 2026 at a glance
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Bioventus' R&D spending?
Bioventus' R&D spending was $3.4M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Bioventus' R&D spending changed?
Over the last 7 quarters it ranged from $2.5M (Q1 2026) to $3.4M (Q3 2026).